TELOMIR PHARMACEUTICALS, INC.

Communiqués Telomir Pharmaceuticals, Inc.

Actions

TELO

US87975F1049

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
4,81 ^USD	+12,38 %		-8,38 %	0,00 %

30/05	Telomir Pharmaceuticals annonce deux étapes décisives pour son principal produit candidat, Telomir-1	CI
13/05	Telomir Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel	17/06	AQ
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1	30/05	AQ
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support	16/05	AQ
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1	07/05	AQ
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.	16/04	AQ
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024	02/04	AQ
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines	26/03	AQ
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th	22/03	AQ
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science	14/03	AQ
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference	07/03	AQ
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal	05/03	AQ
Telomir Pharmaceuticals Announces Closing of Initial Public Offering	13/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Bourse
Actions
Action TELO
Actualités Telomir Pharmaceuticals, Inc.
Communiqués

Sécurisez et Augmentez la Performance de vos Investissements grâce à notre Équipe d'Experts à vos Côtés

Sécuriser mes Investissements

fermer